Aerial Biopharma, a US-based narcolepsy treatment company, has extended its series A round to $9.5m and is looking to raise $12m in total.
In July, Rex Health Ventures, a $10m fund managed on behalf of the eponymous community non-profit hospital, invested $500,000 in Aerial.
Rex Health Ventures’ investment was part of an initial $3.8m equity financing that included angel investor David Adair and venture firm 3G Capital.
Aerial was formed in January 2011 by a team of biopharmaceutical entrepreneurs and its narcolepsy treatment is in phase II clinical trials.
Aerial has a product licensed from the University of North Carolina at Chapel Hill. Aerial was started by the management team of healthcare companies Addrenex Pharmaceuticals and Neuronex.